[
    "{\"step_by_step_thinking\": \"Casimersen is indicated for the treatment of Duchenne muscular dystrophy (DMD) in people who have a confirmed mutation of the DMD gene that is amenable to exon 45 skipping. It has been evaluated in clinical trials and received fast track, priority review, and orphan drug designations from the U.S. Food and Drug Administration (FDA). The approval of casimersen was based on observed increase in dystrophin production in skeletal muscle in patients treated with casimersen. Therefore, based on the available information, casimersen is effective for the treatment of Duchenne muscular dystrophy.\", \"answer_choice\": \"A\"}"
]